slot bet 200 perak Ibotta director Thomas Lehrman sells $4.7 million in stockA Media Looking for Mistakes Portrayed Jimmy Carter as a Failure. It’s Time to Look Deeper

ATHEX: Bourse index advances to 11-week high

WASHINGTON (AP) — A federal judge terminated the gun case against Hunter Biden on Tuesday after President Joe Biden issued a sweeping pardon for his son. U.S. District Judge Maryellen Noreika closed the case the week before Hunter Biden was to be sentenced. He could have faced up to 25 years in prison, though as a first-time offender he likely would have gotten far less time or avoided prison entirely. Prosecutors opposed dismissing the case, arguing in court documents that a pardon shouldn't wipe away the case “as if it never occurred." Hunter Biden was convicted on three felonies after he lied on a federal form to purchase a gun in Delaware by saying he wasn’t a drug user in 2018, a period when he has acknowledged being addicted. The judge's order ends the case but does not toss out the conviction. The Justice Department special counsel is also opposed to dismissing a case filed in California after Hunter Biden failed to pay $1.4 million in taxes . U.S. District Judge Mark Scarsi in Los Angeles indicted he would dismiss the case once the pardon is formally received. Still, Scarsi was critical of the president's assertion that his son was singled out for political reasons, saying two judges had rejected similar arguments from his defense attorneys. The president's Sunday decision to go back on previous pledges and issue his son a blanket federal pardon for actions over the past 11 years has sparked a political uproar in Washington, drawing criticism from many Democrats as well as Republicans and threatening to cloud Biden’s legacy as he prepares to leave office on Jan. 20. Hunter Biden was originally supposed to strike a plea deal with prosecutors last year that would have spared him prison time, but the agreement fell apart after Noreika questioned unusual aspects of it. This story was first published Dec. 3, 2024. It was updated Dec. 4, 2024, to explain that the case was terminated, which ends the case but doesn’t toss out the conviction.

Major Asian chip stocks outside of China rose Tuesday, shrugging off a new round of U.S. semiconductor export curbs aimed at impairing Beijing's capability to produce certain high-end chips. Philadelphia news 24/7: Watch NBC10 free wherever you are Taiwan Semiconductor Manufacturing Company — the world's largest contract chip supplier — saw shares rise 2.4%. Several Japanese chip-related stocks also gained. Tokyo Electron rose 4.7%, Lasertec climbed 6.7%, Advantest gained 3.9% and Renesas Electron advanced 2.2%. Japanese technology conglomerate Softbank , which owns a stake in British chip designer Arm, saw its shares rise 3.6%. The Biden administration's latest chip curbs will also target sales of high-bandwidth memory chips, which could affect the world's two largest memory chip makers — South Korea's SK Hynix and Samsung. Shares of Samsung Electronics and SK Hynix, however, rose 0.9% and 1.8%, respectively. Derrick Irwin, portfolio manager at Allspring Global Investments, told CNBC's "Street Signs Asia," on Tuesday that the high-bandwidth memory controls would impact South Korean players to a degree. "Although our belief is that the impact and sales of high bandwidth memory chips into China are reasonably small from these players in the scheme of things, and they'll probably be able to shift that demand into the U.S. and other markets," he said. The Department of Commerce announced on Monday that it was curbing semiconductor exports to 140 new companies in its latest effort to limit China's ability to access cutting edge chip technology that could be used for advancing its military capabilities. Naura Technology Group , Piotech and ACM Research were among the largest Chinese companies to be included in the export controls list. Shares of Naura Technology and ACM Research fell 3% and 1%, respectively, in China while Piotech rose 1%. China's largest chipmaker, Semiconductor Manufacturing International Corporation, fell 1.5% in Hong Kong. U.S. Secretary of Commerce Gina Raimondo said Monday that the new export controls were the "culmination of the Biden-Harris Administration's targeted approach to impair the PRC's ability to indigenize the production of advanced technologies that pose a risk to our national security." In addition to the entities added, the latest U.S. restrictions include new controls on 24 types of manufacturing equipment and three types of software tools used for developing semiconductors. Last month, the effectiveness of U.S. chip restrictions had been thrown into question when it was reported that a chip made by TSMC had been found in a Huawei product . The latest export restrictions include a new "red flag guidance" to address compliance concerns, and several "critical regulatory changes" to enhance the effectiveness of existing controls.Trump Picks Fox News Medical Contributor To Be Surgeon General

Former US president Bill Clinton hospitalized with fever

Is Syria the next mess for the United States and the free world, including Israel? Syria, part of the ancient world, that figures prominently in Jewish history, came under the sway of the Muslim Ottoman Empire based in Turkey. The Ottoman Empire ruled the land from 1516 to the end of World War I, 1918. Syria was Muslim long before Sultan Selim I defeated the Mamluks in the battle of Marj Dabiq. As recently as 1831, Syria was invaded by the Egyptians. French forces prevailed in World War I and the Occupied Enemy Territory Administration was set up during World War I. A number of short-lived Syrian states came into being during and after World War I. The Syrian republic gained its independence in April of 1946. Immediately thereafter, Syria, along with the other Arab nations, engaged in an attempted war of extermination against Israel and the Jewish people. The recently deposed leader of Syria, Bashar al-Assad is an Alawite, a minority Islamic sect. He and his family have ruled over the Syrians for several generations now, over 50 years. The Assads established a political dynasty that ruled Syria from 1971 until the ouster of Bashar al-Assad on Dec. 8, 2024. All of the nations in Arab Middle East are essentially colonialist creations dreamed up by the victors of World War I. The Saudi family was put in charge of Saudi Arabia. The Hashemites in Jordan, and the Assad family in Syria. The only democracy that has ever existed in the Middle East is, of course, Israel. Who are the new rulers of Syria and what does it mean for the United States and Israel? It is too early to predict just who will wind up governing Syria, but the new leadership appears to be an outgrowth of the terrorist group Al-Qaeda. The current conglomeration of leaders in Syria are not nice people, none of them. They are all folks who have terrorist roots, one way or another. Whether the leadership of Syria will somehow morph into a Western-style democracy is a bet not worth making. The job for the West is to make sure Syria does not become another cancer, aligned with those who seek to destroy the West and Israel. That will not be an easy task. The nature of the Middle East is that various Arab tribes and competing sects of Islam seek to impose their views and values on everyone else. The West, with its tolerance of other people, rights for women, Black people and Jews, is considered to be sinful. Sinful, not in a social way, but with absolute religious rigor. The current and new leaders of Syria should hate Iran and Russia. Both nations propped up Assad and helped him to kill almost 600,000 of his own people displacing 13 million during the civil war. Many of those victims are related to the people who now have power in Syria. However, the fact that the new regime in Syria was persecuted by the Assad faction, with the help of Russia and Iran, does not necessarily mean that the new boys in town will be any good for those of us who adhere to Western values. It does not work that way in the Middle East. For Israel, there is not much more that can be done, other than watchful waiting and destruction of Syria’s advanced weaponry. The new leadership in Syria is thankful to Israel for fighting Hezbollah and weakening that terrorist group which essentially occupies and controls Lebanon and has a major presence in Syria as well. The old adage that the enemy of my enemy is my friend does not work in the Middle East. In fact, it is more typical that the enemy of my enemy is my enemy. The United States, Europe and Israel should consider, as conditions may warrant, being supportive of the new order in Damascus, if it proves itself to be peaceful and tolerant. However, the Western coalition must act promptly to insure that Iran is contained, that Turkey, also a major troublemaker, minds its own business, and that Western interests are treated with respect. While the United States and Western policy to Syria should not be “hands off,” it should not take a deep dive into the pool just yet. Rather, watchful waiting and sending the correct signal is going to be important to the leadership of Syria. The current rebels who have gained control of the country, are not necessarily going to be those who emerge as the kingpins. No doubt there will be an internal power struggle and who will emerge as the top dog in Syria is anyone’s guess. The United States and the West must marginalize and sanction Iran, make it clear to the NATO member Turkey, that it cannot be the new troublemaker in town, and assure that terrorist groups like Hamas and Hezbollah cannot continue to exist. This means, among other things, cutting off the money supply to terrorist groups from our “friends” in Qatar, Saudi Arabia and other oil-rich Arab oil titans. While terrorist operatives in the Middle East are a danger, both to Saudi Arabia and Jordan, neither of those countries is wholly independent of pressure from terrorist-aligned entities. The Middle East is a complex place and United States policy must be straightforward and consistent. No money, financial or political support for the bad guys, and reasonable incentives for the good ones. Perhaps the most important component of U.S. strategy in the Middle East is that it cannot afford to walk away from the region and to risk Syria or any other nation in the Middle East falling into the hands of those who are sworn to the destruction of our Western way of life. Cliff Rieders is a board-certified trial advocate in Williamsport, is past president of the Pennsylvania Trial Lawyers Association and a past member of the Pennsylvania Patient Safety Authority. None of the opinions expressed necessarily represent the views of these organizations.Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering

NoneSaquon Barkley is officially within striking distance of Eric Dickerson’s all-time record for rushing yards in a single season, but it does not seem to be be the most important thing for him right now. The Philadelphia Eagles star Barkley rushed for another 167 yards on Sunday in a 41-7 victory over the Dallas Cowboys that officially clinched the NFC East division for Philly. The outing put Barkley at 2,005 rushing yards for the season and exactly 100 yards away from Dickerson’s all-time record of 2,105 set back in 1984. Barkley can now go for the record in the Eagles’ final game of the season next week against the New York Giants (though Philly sitting their starters for that game is a possibility with the division now all wrapped up). Speaking with reporters after Sunday’s game, Barkley was asked whether he was actively chasing Dickerson’s record. “I’m not overtly trying to get it,” said Barkley, per Mike Garafolo of NFL Network . “I’m not scared of it. But we’ve got bigger things we’re focused on. Whether we play next week or rest, I’m fine with that. I didn’t sign here just to break a record. I want to do something special with the team.” The 13-3 Eagles are still mathematically in the mix for the No. 1 seed in the NFC and a first-round bye. But that is a very unlikely scenario as they still would need to win next week, have the 13-2 Detroit Lions lose twice, and have the 13-2 Minnesota Vikings lose this week. When it comes to the record, Dickerson recently made very clear that he is not rooting for Barkley to break it . Though Dickerson managed to do it in a 16-game season while Barkley gets a 17-game season, Dickerson had 379 carries when he broke the record while Barkley currently has just 345 (and is on pace for 367). Regardless though, the record is there for the taking if Barkley decides he wants to go for it rather than resting for the playoffs. This article first appeared on Larry Brown Sports and was syndicated with permission.

KUWAIT CITY, Dec 23: The Kuwait Institute for Scientific Research (KISR) has completed an innovative research project titled, “Developing Performance Features for Using Integrated Solar-Powered Air-Gap Membrane Distillation Technology for Desalination of Seawater in Kuwait.” This project focused on developing and testing a solar-powered air-gap membrane distillation system for seawater desalination. A test unit was installed at the KISR-affiliated desalination research station, equipped for experimental purposes. Led by scientific researchers Dr. Garudachari Bhadrachari and Dr. Mansour Ahmed, alongside the director of the Water Desalination Technologies Program at the Water Research Center affiliated with KISR; the project includes the assessment of the technology’s performance under real-world conditions in Kuwait. The system utilized Arabian Gulf seawater as feedwater for the pilot unit. The project met its objectives by establishing a comprehensive knowledge base on the performance of the pilot unit under realistic operating conditions. Experimental results demonstrated that the membrane distillation system could produce 23.42 liters of fresh water per day. Furthermore, a conceptual design for large-scale production was developed, using the experimental results along with mathematical modeling and simulations to evaluate the technical and economic feasibility of scaling the technology at various operating capacities. The system offers several social and economic benefits; such as the development of local expertise, enhanced water security, and reduced environmental impacts. It is especially well-suited for remote areas and can be scaled up to meet growing water demands. The researchers recommended further pilot-scale testing of the technology in conjunction with renewable energy and waste heat recovery to reduce energy consumption. The technology demonstrated promising results in reducing blockages, salt deposits and corrosion; which can extend the life of membranes and reduce the need for chemical additives compared to traditional reverse osmosis systems. By Abdulrahman Al-Shammari Al-Seyassah/Arab Times Staff

Telematics for Rental and Leasing Fleets Report, 3rd Edition: Geotab, Targa Telematics, OCTO Telematics, CalAmp, Webfleet, Powerfleet, Munic, MySmartObject, Connected Cars and RentalMatics DominatePalvella Therapeutics to debut on Nasdaq under the ticker symbol “PVLA” as a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic diseases Strong balance sheet with approximately $80.0 million of cash and cash equivalents, including proceeds from a PIPE financing co-led by BVF Partners, L.P. and Frazier Life Sciences Cash expected to fund operations into the second half of 2027, including through Phase 3 SELVA clinical trial of QTORINTM 3.9% rapamycin anhydrous gel (QTORINTM rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs) and Phase 2 clinical trial in cutaneous venous malformations (cutaneous VMs) Microcystic LMs is a chronically debilitating and lifelong genetic disease affecting an estimated more than 30,000 diagnosed patients in the U.S. QTORINTM rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for microcystic LMs and cutaneous VMs WAYNE, Pa., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced the completion of its previously announced merger with Pieris Pharmaceuticals, Inc. (Pieris). The combined company will operate under the name Palvella Therapeutics, Inc., and its shares are expected to begin trading on the Nasdaq Capital Market on December 16, 2024, under the ticker symbol "PVLA". Palvella will continue to be led by Wes Kaupinen, its Founder and Chief Executive Officer, and other members of the Palvella management team. The transaction was approved by Pieris stockholders at a special meeting held on December 11, 2024, and the transaction had been previously approved by Palvella stockholders. "With strong support from leading healthcare-dedicated investors, Palvella is well positioned to enter the public markets and pursue our vision of becoming the leading rare disease company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases," said Mr. Kaupinen. “This transaction will enable us to accelerate late-stage development of QTORINTM rapamycin, our lead product candidate, for microcystic LMs and cutaneous VMs while also further advancing additional novel product candidates from our QTORINTM platform." Concurrent with the merger, Palvella completed a previously announced oversubscribed $78.9 million private placement co-led by BVF Partners, L.P., an existing investor, and Frazier Life Sciences, a new investor, and with participation from a syndicate of leading healthcare-dedicated investors. Additional new investors include Blue Owl Healthcare Opportunities, Nantahala Capital, DAFNA Capital Management, ADAR1 Capital Management, and a healthcare dedicated fund. Existing investors Samsara BioCapital, Petrichor, CAM Capital, Ligand Pharmaceuticals, Integrated Finance Group (an AscellaHealth partner company), BioAdvance, and Gore Range Capital also participated in the financing. Palvella's cash and cash equivalents of approximately $80.0 million is expected to fund operations into the second half of 2027, including through results from the SELVA Phase 3 clinical trial of QTORINTM rapamycin for the treatment of microcystic LMs and Phase 2 clinical trial of QTORINTM rapamycin in cutaneous VMs. Palvella’s research team developed QTORINTM, a patented and versatile platform designed to generate novel topical therapies that penetrate the deep layers of the skin to locally treat a broad spectrum of serious, rare genetic skin diseases. Well-accepted mechanisms of action of rapamycin and other therapeutic agents represent potential therapies for rare genetic skin diseases. However, the adverse event profile of those agents through systemic exposure poses significant barriers to patient adoption. Palvella’s QTORINTM product candidates are designed for targeted, localized delivery of therapeutic agents to pathogenic tissue of interest while minimizing systemic absorption and thereby reducing the risk of unwanted adverse events associated with systemic therapy. Palvella's lead product candidate QTORINTM rapamycin is a novel, patented 3.9% rapamycin anhydrous gel currently under development for the treatment of microcystic LMs, cutaneous VMs, and other serious, functionally debilitating skin diseases driven by the overactivation of the mammalian target of rapamycin (mTOR) pathway. QTORINTM rapamycin has received FDA Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation for microcystic LMs and is the recent recipient of up to a $2.6 million FDA Orphan Products Grant. QTORINTM rapamycin has also received Fast Track Designation for venous malformations. QTORINTM rapamycin is protected by issued composition patents covering anhydrous gel formulations of rapamycin, as well as methods of use, in the U.S., Japan, Australia, China and Israel and pending patent applications broadly covering anhydrous gel formulations of rapamycin, as well as methods of use, in the U.S. and other countries. In the third quarter of 2024, Palvella initiated SELVA, a 24-week, Phase 3, single-arm, baseline-controlled clinical trial of QTORINTM rapamycin administered once daily for the treatment of microcystic LMs. The primary efficacy endpoint is the change from baseline in the overall microcystic LM Investigator Global Assessment (mLM-IGA) at week 24. The Phase 3 study is enrolling approximately 40 subjects, age six or older, at leading vascular anomaly centers across the U.S. Transaction Details Based on the final exchange ratio of approximately 0.30946 shares of Pieris common stock for each share of Palvella common stock, at the closing of the merger, there are approximately 13.95 million shares of the combined company's common stock outstanding on a diluted basis, with prior Pieris stockholders owning approximately 11% on a diluted basis and prior Palvella stockholders (including investors in the private placement) holding approximately 89% of the combined company's outstanding common stock on a diluted basis. In connection with the closing of the merger, Pieris issued a non-transferable contingent value right (CVR) to Pieris shareholders of record immediately prior to the closing, which does not include the former holders of shares of Palvella or the private financing investors. Holders of the CVR will be entitled to receive payments from proceeds received by the combined company, if any, under Pieris' existing partnership agreements with Pfizer and Boston Pharmaceuticals, in addition to other potential licensing agreements involving certain of Pieris' legacy assets, as well as certain potential payments related to historical research and development tax credits, which may or may not be realized. TD Cowen served as lead placement agent and Cantor served as a placement agent for Palvella's concurrent financing. Troutman Pepper Hamilton Sanders LLP served as legal counsel to Palvella. Cooley LLP served as legal counsel to the placement agents. Stifel served as the exclusive financial advisor to Pieris and Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C. served as legal counsel to Pieris. About Microcystic Lymphatic Malformations Microcystic LMs are a rare, chronically debilitating genetic disease caused by dysregulation of the phosphatidylinositol 3-kinase (PI3K)/mTOR pathway. The disease is characterized by malformed lymphatic vessels that protrude through the skin and persistently leak lymph fluid (lymphorrhea) and bleed, often leading to recurrent serious infections and cellulitis that can cause hospitalization. The natural history of microcystic LMs are persistent and progressive without spontaneous resolution, with symptoms generally worsening during life, including increases in the number and size of malformed vessels that lead to complications and lifetime morbidity. There are currently no FDA-approved treatments for the estimated more than 30,000 diagnosed patients with microcystic LMs in the United States. About Palvella Therapeutics Founded and led by rare drug disease drug development veterans, Palvella Therapeutics (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORINTM platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella’s lead product candidate, QTORINTM 3.9% rapamycin anhydrous gel (QTORINTM rapamycin), is currently in the Phase 3 SELVA clinical trial in microcystic lymphatic malformations (microcystic LMs) and a Phase 2 trial in cutaneous venous malformations. For more information, please visit www.palvellatx.com or follow the Company on LinkedIn. QTORINTM rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency. This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (Securities Act)). These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Palvella and Pieris, as well as assumptions made by, and information currently available to, management of Palvella and Pieris. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Statements that are not historical facts are forward-looking statements. Forward-looking statements include, but are not limited to, the sufficiency of the combined company’s capital resources; the combined company’s cash runway; the expected timing of the closing of the proposed transactions; statements regarding the potential of, and expectations regarding, Palvella’s programs, including QTORINTM rapamycin, and its research-stage opportunities, including its expected therapeutic potential and market opportunity; the expected timing of initiating, as well as the design of Palvella’s Phase 2 clinical trial of QTORINTM rapamycin in cutaneous venous malformations. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the limited operating history of each company; the significant net losses incurred since inception; the ability to raise additional capital to finance operations; the ability to advance product candidates through preclinical and clinical development; the ability to obtain regulatory approval for, and ultimately commercialize, Palvella’s product candidates, including QTORINTM rapamycin; the outcome of early clinical trials for Palvella’s product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements; the fact that data and results from clinical studies may not necessarily be indicative of future results; Palvella’s limited experience in designing clinical trials and lack of experience in conducting clinical trials; the ability to identify and pivot to other programs, product candidates, or indications that may be more profitable or successful than Palvella’s current product candidates; the substantial competition Palvella faces in discovering, developing, or commercializing products; the negative impacts of the global events on operations, including ongoing and planned clinical trials and ongoing and planned preclinical studies; the ability to attract, hire, and retain skilled executive officers and employees; the ability of Palvella and Pieris to protect their respective intellectual property and proprietary technologies; reliance on third parties, contract manufacturers, and contract research organizations. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in Pieris’ most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC, as well as the registration statement on Form S-4 filed with the SEC by Pieris in connection with the merger. Palvella and Pieris can give no assurance that the conditions to the proposed transactions will be satisfied. Except as required by applicable law, Palvella and Pieris undertake no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release. Palvella Therapeutics Contact Information Investors Wesley H. Kaupinen Founder and CEO, Palvella Therapeutics wes.kaupinen@palvellatx.com Media Stephanie Jacobson Managing Director, Argot Partners palvella@argotpartners.com

None

Travis Hunter and Ashton Jeanty give this year's Heisman Trophy ceremony a different vibe

17-year-old Loki star Jack Veal shares update after revealing he’s homelessDay 5 of the fourth Test match will take place on Monday, December 30, 2024, at the iconic Melbourne Cricket Ground (MCG). As the India vs Australia Border-Gavaskar Trophy 4th Test heads into its thrilling final day, all eyes are on the Melbourne Cricket Ground (MCG) for what promises to be an exciting conclusion to an already intense battle. After a gripping Day 4, with Australia leading by 333 runs at stumps, the stage is set for a dramatic Day 5 on December 30, 2024. Let's dive into the crucial details on where to watch the match, the time, and the expected weather conditions that might play a pivotal role. When and Where Is Day 5 of the India vs Australia 4th Test? Day 5 of the fourth Test match will take place on Monday, December 30, 2024, at the iconic Melbourne Cricket Ground (MCG). The action will begin at 5:00 AM IST (10:30 AM local time), and cricket fans worldwide are eagerly awaiting the final showdown between these two cricketing giants. Standout Performances on Day 4 The action on Day 4 of the Test match was nothing short of enthralling. Jasprit Bumrah put India in a hopeful position by taking 4 wickets for 99 runs, including the key scalp of Alex Carey, and became the latest Indian pacer to reach the 200-wicket milestone in Test cricket. His fiery spell in the second innings was a ray of hope for India, but Australia’s lower-order resistance, aided by Mohammed Siraj’s 3/78, ensured they ended the day firmly in the driver’s seat. Australia finished at 228/9, leading by 333 runs, and now have one final push to secure a victory. With a strong total on the board, Australia's chances of a win seem high, but with Bumrah and Siraj in fine form, India will look to exploit any weaknesses on the final day. Where to Watch Day 5 of India vs Australia 4th Test? In India: For Indian fans, the match will be live-streamed on the Disney+ Hotstar app and website. Viewers can also catch the live broadcast on Star Sports Network and DD Sports. In Australia: Australian audiences can watch Day 5 live on Fox Cricket and Channel 7. For streaming, Kayo Sports and 7Plus will provide access to the game. International Broadcast: United Kingdom and Ireland: SKY Sports New Zealand: TNT Sports Sri Lanka: Supreme TV South Africa: Super Sport Pakistan: Ten Sports, Tapmad Weather Forecast for Day 5 at MCG The weather in Melbourne could play a critical role in determining the pace of the game. With cloud cover expected at 93%, the pacers from both sides will be looking to capitalize on the conditions. The temperature is set to rise to 27°C, but the overcast conditions could offer assistance to fast bowlers, especially in the early overs. This could prove crucial as Bumrah and Siraj will look to use any movement to their advantage. Final Day: India’s Challenge With the series tied at 1-1, Day 5 will decide whether India can push for a win or whether Australia will extend their dominance. As it stands, India needs a remarkable comeback to bowl Australia out and chase down the sizeable target. The Indian bowlers will be relying on swing and bounce, and with players like Bumrah and Siraj leading the charge, there's every chance they can pull off an upset. However, Marnus Labuschagne and other key Australian batters will be looking to ensure that Australia seals the deal with a dominant performance. As Labuschagne himself noted, the pitch has become less predictable as the match progresses, with the ball starting to skid through and hitting the stumps more frequently. Stay informed on all the latest news , real-time breaking news updates, and follow all the important headlines in india news and world News on Zee News.